Brexucabtagene autoleucel
Brexucabtagene autoleucel is the CAR-T therapy for mantle cell lymphoma and adult acute lymphoblastic leukaemia, giving long remissions after BTK inhibitors fail.
ZUMA-2 (NEJM 2020): 93% response, 67% CR in BTKi-exposed MCL, with ~30-month median PFS in updates. ZUMA-3: 71% CR/CRi in adult R/R B-ALL (approval 2021). Cytokine release and neurotoxicity rates are high (grade ≥3 neuro ~30%).
- Medicare
- Part B (clinician-administered)NCD 110.24
Autologous CAR-T covered nationally under NCD 110.24 for FDA-labelled indications at facilities enrolled in the FDA REMS. Inpatient administration is paid under Part A (MS-DRG 018); outpatient administration is a Part B drug. The product itself is bundled into the facility payment. HCPCS Q2053.
- Commercial insurance
- covered with prior authorisation
Covered with prior authorisation and usually a single-case agreement with a certified treatment centre; many plans restrict to centres of excellence and require documentation of prior lines of therapy.
- Assistance programmes
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B) · CMS NCD 110.24: Chimeric antigen receptor (CAR) T-cell therapy · Medicare.gov: Inpatient hospital care (Part A). Not medical or financial advice; verify with your plan.
- Appraised for
- Relapsed or refractory mantle cell lymphoma after a BTK inhibitor
- Notes
- Adult B-ALL indication appraised separately (2023).
- Cancer Drugs Fund
- Entered the Cancer Drugs Fund under a managed access agreement; check the current CDF list for whether it has since moved to routine commissioning.
- NHS England
- Routinely funded for the appraised indication (or via managed access)
Sources: NICE TA677 · NHS England Cancer Drugs Fund list · SMC advice: brexucabtagene autoleucel. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2020 | Relapsed/refractory mantle cell lymphoma |
| US | 2021 | Relapsed/refractory B-ALL in adults |
| EU | 2020 | MCL after ≥2 lines including a BTK inhibitor |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Brexucabtagene autoleucel" OR ABSTRACT:"Brexucabtagene autoleucel" OR TITLE:"Tecartus" OR ABSTRACT:"Tecartus") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Brexucabtagene autoleucel, not a curated reading list.
Pages like this
not linked directly; found by shared links- TargetCD7
Shares Acute lymphoblastic leukaemia, CAR-T cell therapy and the tag gap-fill.
- ProductIdelalisib
Shares Gilead Sciences (incl. Kite) and the tag gap-fill.
- TargetCD73 / adenosine axis
Shares Gilead Sciences (incl. Kite) and the tag gap-fill.
- ProductTemsirolimus
Shares Mantle cell lymphoma and the tag gap-fill.
- TargetCD79b
Shares Mantle cell lymphoma and the tag gap-fill.
- ProductAsparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)
Shares Acute lymphoblastic leukaemia and the tag gap-fill.
- TargetEpCAM
Shares CAR-T cell therapy and the tag gap-fill.
- TargetClaudin 6
Shares CAR-T cell therapy and the tag gap-fill.